Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
22 auth.
B. Langdahl,
C. Libanati,
D. Crittenden,
M. Bolognese,
Jacques P. Brown,
N. Daizadeh,
E. Dokoupilova,
K. Engelke,
J. Finkelstein,
H. Genant,
...
S. Goemaere,
L. Hyldstrup,
E. Jódar-Gimeno,
T. Keaveny,
D. Kendler,
P. Lakatos,
J. Maddox,
J. Malouf,
F. Massari,
J. Molina,
M. Ulla,
A. Grauer
|
|
8 |
2017 |
Social Media Posts